Insider · CIK 0001352413
Mark Christopher Capone
Files at MLAB (MESA LABORATORIES INC /CO/), SERA (SERA PROGNOSTICS, INC.). First filing Mar 10, 2026, latest Mar 10, 2026.
In brief
Mark Christopher Capone files SEC Form 4 as director at MLAB (MESA LABORATORIES INC /CO/), and also at SERA (SERA PROGNOSTICS, INC.). Since Mar 10, 2026, Mark Christopher Capone has reported 1 open-market buy worth $99k and 0 open-market sells worth $0, the latest filed on Mar 10, 2026.
A track record needs three past buys with six months of prices behind them; Mark Christopher Capone has 0, so none is measured yet.
The newest scored trade: bought $99k of MLAB on Mar 10, 2026, filed Mar 10, 2026, scored 58 (moderate). In the last 12 months: 1 buy worth $99k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
MLAB: MESA LABORATORIES INC /CO/
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 58Moderate | MESA LABORATORIES INC /CO/ | $99k 1,301 shares | +61% | +28% from low-43% from high |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | MLAB MESA LABORATORIES INC /CO/ | AGrant or award Restricted Stock Units - 4derivative | +2,423 | $0.00 | $0 | 2,423 | 32 d ago |
| Aug 15, 2026 | MLAB MESA LABORATORIES INC /CO/ | MOption exercise Common Stock | +2,784 | $0.00 | $0 | 6,213 | Aug 17, 2026 |
| Aug 15, 2026 | MLAB MESA LABORATORIES INC /CO/ | MOption exercise Restricted Stock Units - 3derivative | -2,784 | $0.00 | $0 | 0 | Aug 17, 2026 |
| Jul 10, 2026 | SERA SERA PROGNOSTICS, INC. | AGrant or award Class A Common Stock | +42,404 | $0.00 | $0 | 42,404 | Jul 14, 2026 |
| Jul 10, 2026 | SERA SERA PROGNOSTICS, INC. | AGrant or award Class A Common Stock | +1,975 | $0.00 | $0 | 44,379 | Jul 14, 2026 |
| Jul 10, 2026 | SERA SERA PROGNOSTICS, INC. | AGrant or award Stock Option (right to buy)derivative | +62,766 | $0.00 | $0 | 62,766 | Jul 14, 2026 |
| Jul 10, 2026 | SERA SERA PROGNOSTICS, INC. | AGrant or award Stock Option (right to buy)derivative | +3,037 | $0.00 | $0 | 3,037 | Jul 14, 2026 |
| Mar 10, 2026 | MLAB MESA LABORATORIES INC /CO/ | POpen-market purchase Common Stock | +1,301 | $76.35 | $99k | 3,429 | Mar 10, 2026 |
| Aug 15, 2025 | MLAB MESA LABORATORIES INC /CO/ | MOption exercise Common Stock | +1,404 | $0.00 | $0 | 2,128 | Aug 18, 2025 |
| Aug 15, 2025 | MLAB MESA LABORATORIES INC /CO/ | MOption exercise Restricted Stock Units - 2derivative | -1,404 | $0.00 | $0 | 0 | Aug 18, 2025 |
| Aug 15, 2025 | MLAB MESA LABORATORIES INC /CO/ | AGrant or award Restricted Stock Units - 3derivative | +2,784 | $0.00 | $0 | 2,784 | Aug 18, 2025 |
Questions about Mark Christopher Capone
Answered from the filings on this page, as of the latest one.
Is Mark Christopher Capone buying or selling?
In the last 12 months Mark Christopher Capone reported 1 open-market buy worth $99k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $99k of MLAB on Mar 10, 2026. Grants, option exercises and tax withholding are not counted.
How did Mark Christopher Capone's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mark Christopher Capone has 0.
Where does Mark Christopher Capone file Form 4?
Mark Christopher Capone has filed Form 4 at MLAB (MESA LABORATORIES INC /CO/); SERA (SERA PROGNOSTICS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.